Labovita - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 10,606 | 4,835 | 4,832 | 18,180 | 4,755 | 2,369 | 11,355 | 1,950 |
| Profit before tax | 2,352 | -3,702 | -1,750 | -917 | -1,056 | -5,420 | 990 | -3,231 |
| Net profit | 2,234 | -3,702 | -1,750 | -917 | -1,056 | -5,420 | 990 | -3,231 |
| Equity | 26,373 | 15,612 | 13,862 | 12,945 | 11,889 | 6,469 | 7,459 | 4,228 |
| Liabilities | 333 | 215 | 215 | 1,598 | 215 | 216 | 216 | 216 |
| Non-current assets | 114 | 16 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current assets | 26,584 | 15,762 | 14,028 | 14,495 | 12,056 | 6,637 | 7,627 | 4,384 |
| Total assets | 26,698 | 15,778 | 14,028 | 14,495 | 12,056 | 6,637 | 7,627 | 4,384 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 569 | 569 | 569 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -36.3% | -54.4% | -0.1% | +276.2% | -73.8% | -50.2% | +379.3% | -82.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 8.4% | -23.5% | -12.5% | -6.3% | -8.8% | -81.7% | 13.0% | -73.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 8.5% | -23.7% | -12.6% | -7.1% | -8.9% | -83.8% | 13.3% | -76.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 21.1% | -76.6% | -36.2% | -5.0% | -22.2% | -228.8% | 8.7% | -165.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 22.2% | -76.6% | -36.2% | -5.0% | -22.2% | -228.8% | 8.7% | -165.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 10,606 | 3,054 | 2,416 | 9,090 | 2,378 | 1,185 | 5,678 | 975 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Labovita - Social security debts
The company had no debts to Sodra
Labovita - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Labovita, UAB (code 300147277) is a Private Limited Liability Company engaged in wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €1.9K, down 82.8% year on year and well below the €11.4K recorded in 2024. Net profit turned into a loss of €3.2K in 2025, after a profit of €990 in 2024 and a loss of €5.4K in 2023. The latest year therefore reflects a clear weakening in operating performance after a brief improvement in 2024. Total assets fell to €4.4K at the end of 2025 from €7.6K a year earlier, while equity declined to €4.2K. Liabilities remained at €216, leaving the balance sheet strongly equity-funded. The equity ratio stood at 96.4% and debt-to-equity at 0.05. Asset turnover was 0.44x in 2025, and revenue per employee was €975. Over the three-year period, revenue rose strongly in 2024 before dropping sharply in 2025, while profitability moved from loss to profit and then back to loss.